In a potential paradigm shift for HIV management, pharmaceutical giants Gilead Sciences and Merck have unveiled promising Phase 3 clinical data for an investigational, once-weekly oral treatment regimen. The combination, pairing Merck’s islatravir with Gilead’s lenacapavir, has demonstrated sustained virologic suppression in over 1,200 adults living with HIV, potentially offering a more convenient alternative to the daily pill burden that has defined the standard of care for decades.
The findings, presented at the 26th International AIDS Conference, suggest that the future of HIV therapy may be moving away from the "daily ritual" toward a more flexible, reduced-dosing schedule. If granted regulatory approval, this regimen would mark the first once-weekly oral maintenance therapy for adults with suppressed HIV, offering a significant improvement in quality of life for millions of patients worldwide.
The Core Innovation: A Once-Weekly Breakthrough
The investigational combination consists of 2 mg of islatravir—Merck’s next-generation nucleoside reverse transcriptase translocation inhibitor (NRTTI)—and 300 mg of lenacapavir, Gilead’s first-in-class capsid inhibitor.
While current market leaders like Gilead’s own Biktarvy have been immensely successful, they require strict daily adherence. The ISL/LEN combination utilizes the unique pharmacokinetic profiles of both drugs, which allow for a longer half-life, enabling the medication to remain effective in the body for a full seven days. For patients who struggle with the psychological weight or the daily reminder of their diagnosis associated with daily medication, a weekly regimen could substantially reduce treatment fatigue and improve long-term adherence.
Chronology of Clinical Development
The road to the current Phase 3 results has been marked by a rigorous, stepwise approach to safety and efficacy.
- October 2024: Gilead and Merck announced positive Phase 2 data. In this study, 104 virologically suppressed adults were transitioned from Biktarvy to the weekly ISL/LEN regimen. At 48 weeks, 94.2% of the switch group remained suppressed, with no emergent drug resistance detected. This trial served as the "proof of concept" that emboldened the companies to move into larger, definitive Phase 3 studies.
- November 2024: At the HIV Glasgow conference, researchers presented extended data from the Phase 2 trial. A key takeaway was the necessity for clinicians to address Hepatitis B immunization, as the switch from tenofovir-containing regimens (like Biktarvy) to ISL/LEN removes the "dual-coverage" that Biktarvy provides against Hepatitis B.
- April 2026: The FDA approved Merck’s Idvynso (doravirine/islatravir), providing a regulatory "green light" for the use of islatravir in HIV care, which helped bolster confidence in the safety profile of the molecule.
- June 8, 2026: The companies released topline results for the ISLEND-1 and ISLEND-2 trials.
- July 2026: Detailed results were presented at the 26th International AIDS Conference, confirming the efficacy of the regimen at the 48-week mark.
Supporting Data: ISLEND-1 and ISLEND-2
The Phase 3 program consisted of two distinct but complementary trials, ISLEND-1 (NCT06630286) and ISLEND-2 (NCT06630299), which together enrolled 1,209 participants.
ISLEND-1: The Gold Standard Comparison
In this double-blind, randomized trial, researchers compared the weekly ISL/LEN regimen directly against the current market giant, Biktarvy. The results were striking: none of the participants who switched to the weekly regimen had HIV-1 RNA levels at or above 50 copies/mL at Week 48. In the Biktarvy arm, that figure was 0.3%. Adverse events were comparable, with roughly 13% of participants in both groups reporting treatment-related issues, primarily mild nausea or headaches.
ISLEND-2: Real-World Flexibility
ISLEND-2 adopted an open-label design, allowing participants to switch from a variety of two- or three-drug regimens to the once-weekly combination. This trial sought to mimic "real-world" clinical practice. The efficacy remained robust, with only 0.3% of the ISL/LEN group showing viral rebound compared to 1.3% in the control group.
Patient satisfaction metrics were a highlight of this trial. Using the HIV Patient Perspective of Regimen Change instrument, participants reported feeling significantly less burdened by the weekly dosing schedule. While the adverse event reporting was slightly higher in the ISL/LEN arm (18%) compared to the standard-of-care group (<1%), investigators noted that this was likely a result of the trial design: those on the standard-of-care had been on their regimens for months, having already acclimated to any potential side effects.
Implications for the HIV Treatment Market
The commercial landscape for HIV medication is dominated by highly effective, single-tablet regimens. Biktarvy alone generated over $14 billion in 2025, accounting for nearly 70% of Gilead’s HIV franchise. The introduction of a weekly regimen presents a strategic "cannibalization" risk that Gilead appears ready to embrace.
Shifting from Daily to Weekly
Gilead’s willingness to disrupt its own market leader suggests that the company is playing the long game. With Biktarvy’s patent protection lasting until 2036, Gilead is positioning itself to own the next generation of HIV therapy. By offering both a daily successor (bictegravir/lenacapavir) and a weekly option, Gilead aims to capture every segment of the patient population, from those who prefer the simplicity of a daily routine to those seeking the freedom of weekly dosing.
The Rise of Long-Acting Injectables
The primary competition for oral weekly regimens is not actually another pill, but the injectable market. ViiV Healthcare’s Cabenuva—administered every two months—has seen massive growth, with a 42% increase in revenue in 2025. The medical community is currently divided: some patients prefer the convenience of an injection that they can "forget about" for months at a time, while others prefer the autonomy of taking a pill at home, avoiding the need for frequent clinic visits.
The Path Forward: Clinical and Regulatory Considerations
While the data is undeniably positive, the path to widespread adoption involves more than just proving viral suppression.
- Hepatitis B Management: As noted by Dr. Amy Colson of the Zinberg Clinic, the transition away from tenofovir-based regimens necessitates a shift in clinical practice. Healthcare providers will need to ensure that patients switching to ISL/LEN are adequately screened and vaccinated against Hepatitis B, as they will lose the preventative benefits of tenofovir.
- Patient Preference: The psychological impact of moving from a daily reminder of HIV status to a weekly one cannot be overstated. Qualitative data from ISLEND-2 suggests that "treatment burden" is a major driver of patient satisfaction, which may give the weekly pill a competitive edge over both daily pills and injectable therapies that require clinical scheduling.
- Regulatory Hurdles: Following the presentation of the Phase 3 data, Gilead and Merck are expected to file for regulatory approval with the FDA and other global agencies. If the regulatory review proceeds without delays, the medical community could see the first once-weekly oral HIV treatment reach pharmacies by late 2027 or early 2028.
Final Thoughts
The success of the islatravir and lenacapavir combination represents a milestone in infectious disease management. By transforming HIV from a condition that demands daily vigilance into one that requires only weekly attention, Gilead and Merck are not merely offering a new drug; they are offering a new lifestyle. As the data matures and moves into the hands of regulators, the focus will now shift to how these treatments are integrated into existing clinical pathways and how they will compete in an increasingly crowded, yet highly innovative, HIV marketplace.
The next decade of HIV care promises to be defined by this transition—a transition that prioritizes not just viral suppression, but the personal freedom and mental well-being of the millions of individuals living with the virus.
About the Author
